MERCATOR
29.3.2022 09:32:13 CEST | Business Wire | Press release
The Netherlands has been identified as the best jurisdiction to base pharma-industry entities when taking into account cost and time efficiencies, according to data compiled by the global entity portfolio management (GEPM) leader Mercator® by Citco , in its Pharmaceutical GEPM: Special Report .
The pandemic has accelerated the way pharmaceutical companies streamline their operations and Mercator’s granular data found that most of the businesses it looked at were organizationally agile with robust business continuity plans in place.
The figures show the United States is the most efficient jurisdiction for the timely completion of tasks and Luxembourg the most cost effective but, when combining these factors together, the Netherlands had the best metrics on cost and completion time.
The country’s status as a European financial center and its historic links to international trade have created an environment that allows multinational pharmaceutical companies to manage entities there with relative ease.
Singapore and Belgium both scored highly when combining the two characteristics, while Brazil, South Korea and China had the lowest ranking overall.
Europe remains the hub for a significant portion of pharmaceutical companies outside of North America, primarily led by renowned life sciences hubs in Switzerland, Germany and France - with India performing a similar role within the APAC region.
Kariem Abdellatif, Head of Mercator, said: “The world is a global village, but this report shows that there are still huge differences between countries. However, the insights revealed by this report are not a recommendation of where pharmaceutical multinationals should base their entities or subsidiaries as that will always be driven by demand and necessity. Rather, it is an exercise in setting expectations and providing pharmaceutical General Counsels and Company Secretaries with foresight on the relative cost and time it takes to manage entities and their activities in each jurisdiction.
“It is interesting to see the Netherlands top the rankings in this instance, but forward-thinking multinational companies should be embracing technology platforms that let them do business seamlessly across borders and jurisdictions.”
Many of the projects Mercator helped facilitate for its pharma clients over the past two years have involved high-impact corporate initiatives to optimize value chains, minimize the commercial impacts of the ongoing disruptions and control costs.
To read the full report, please visit: https://mercator.net/our-thinking/publications/pharmaceutical-gepm-special-report/ .
This report follows the Mercator Entity Management (MEM) Report which outlined the challenges that multinationals across a variety of sectors face when managing a global portfolio of entities.
- ENDS -
Notes to editors:
This report provides direct insight into the practice and dynamics of Global Entity Portfolio Management (GEPM) within the pharmaceuticals sector - based on real-life data – when these businesses have been at the epicenter of one of the most significant global disrupters in modern times.
This data is drawn directly from Mercator’s proprietary GEPM technology platform – Entica™ – which individually records all the activities undertaken for clients. Mercator’s data from the pharmaceutical sector represents more than $600bn in market capital, with entities spread across 70 jurisdictions worldwide. As such, Mercator is uniquely positioned to analyze data on a highly detailed level; unlike survey-driven reports, this analysis is specific to the overseas entities of multinational pharmaceutical companies.
About Mercator® by Citco
A pioneer in Global Entity Portfolio Management (GEPM), Mercator creates lasting partnerships with its clients to understand their individual needs and offer ease, efficiency and visibility through a clear layer of oversight. Mercator’s unrivalled knowledge of GEPM and proprietary technology – Entica™ – is evolving the way companies view and manage their portfolio of entities, helping them navigate an increasingly complex regulatory environment.
Mercator is named after Gerardus Mercator (1512-1594), a cartographer most famous for the “Mercator Projection” – regarded as the greatest advance ever made in marine cartography; it facilitated navigation on trans-oceanic voyages and played a significant role in shaping global trade today. As the trans-oceanic merchants of the past are the multinational conglomerates of the present, Mercator aims to provide them with the metrics they require to manage their global portfolio of entities.
About the Citco group of companies (Citco)
The Citco group of companies (Citco) is a network of independent companies worldwide. These companies are leading providers of asset-servicing solutions to the global alternative investment industry. With over $1.8 trillion in assets under administration and 8,200 staff deployed across 40 countries, Citco’s unique culture of innovation and client-driven solutions have provided Citco’s clients with a trusted partner for more than four decades.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005663/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strategic Partnership Between Record Asset Management and Admicasa2.7.2026 19:00:00 CEST | Press release
RAM Swiss Holding AG announces a strategic partnership with Admicasa Holding AG (Admicasa). RAM Swiss Holding AG is a subsidiary of LSE-listed Record Financial Group (Record) and part of the Record Asset Management (RAM) group of companies. The partnership is a milestone in the growth of Admicasa and marks an important step in the continued expansion of Record’s private markets platform. Subject to regulatory approval, the agreement, signed on 1st July 2026, provides RAM Swiss Holding AG with a 50% participation in the Admicasa Fondsleitung AG, part of Admicasa, and establishes a long-term partnership to develop investment opportunities in the Swiss and Global real estate market with a plan to expand into other asset classes in the medium term. RAM is the European asset management arm of Record, the LSE-listed specialist investment group managing USD 115 billion of assets on behalf of institutional clients worldwide. Record's client base comprises pension funds, foundations, sovereign
IQM Quantum Computers Becomes First European Quantum Computing Company Listed on a Major U.S. Exchange2.7.2026 16:47:00 CEST | Press release
IQM begins trading on Nasdaq Global Select Market under the ticker symbol “IQMX” Company enters next phase of growth as a publicly traded leader in full-stack superconducting quantum computing IQM maintains a strong pro forma cash position of EUR 337 million IQM Quantum Computers (Nasdaq: IQMX) (“IQM”, “IQM Quantum Computers” or the “Company”), a global leader in full-stack superconducting quantum computers, today became a publicly traded company following the completion of its business combination with Real Asset Acquisition Corp. (“RAAQ”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260702960460/en/ IQM Quantum Computers Becomes First European Quantum Computing Company Listed on a Major U.S. Exchange The company’s American Depositary Shares begin trading today on the Nasdaq Global Select Market under the ticker symbol “IQMX”. The listing marks a major milestone for IQM establishing the company as the first European quan
GigaDevice Launches First GD24CL Series I²C EEPROM, Further Expanding Its Non-Volatile Memory Portfolio2.7.2026 16:00:00 CEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, announced today the launch of its new GD24CL series I²C EEPROM. The series delivers outstanding performance, comprehensive security protection mechanisms, and excellent reliability that addresses the stringent requirements for stable and long-term storage of critical configuration data. These offered features will benefit applications in industrial, energy, Internet-of-Things (IoT), data centers, and networking. As GigaDevice’s first EEPROM product series, the launch further enhances the company’s non-volatile memory portfolio and provides customers with more dynamic storage solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260702394554/en/ GigaDevice Launches First GD24CL Series I²C EEPROM, Further Expanding Its Non-Volatile Memory Portfolio. The GD24CL series is designed with high
Medical University of Graz Enrolls First Patient in DEEPER CHALLENGE Trial Evaluating Spur® Peripheral Retrievable Scaffold System in a Select CLTI Cohort2.7.2026 13:00:00 CEST | Press release
Reflow Medical, Inc. announces that the Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial. This investigator-initiated, single-center, single-arm, prospective study, supported by a grant, investigates early vessel recoil following below-the-knee treatment using the Spur® Peripheral Retrievable Scaffold System in combination with a commercially available drug-coated balloon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701995624/en/ The study investigates early vessel recoil following below-the-knee treatment using the Spur® Peripheral Retrievable Scaffold System in combination with a commercially available drug-coated balloon. The study plans to enroll up to 40 patients with chronic limb-threatening ischemia (CLTI) across two distinct cohorts: patients with diabetes and patients with end-stage renal disease receiving hemodialysis for at least six months, with women comprisi
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2.7.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to eight newly hired non-executive employees. The equity awards were granted on July 1, 2026 and consisted of options to purchase an aggregate of 63,685 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 30,300 shares. The options have an exercise price per share equal to $13.29, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted sh
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom